2. Search Result
Search Result
Results for "

K12

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Peptides

1

Natural
Products

9

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-163944
    LL-K12-18

    		Molecular Glues CDK Cancer
    LL-K12-18 is a two-site molecular glue that enhances the protein-protein interaction of the CDK12-DDB1 complex, stabilizing the CDK12-DDB1 complex and promoting the degradation of cyclin K (EC50=0.37 nM). LL-K12-18 exhibits strong gene transcription inhibition and anti-proliferation effects in tumor cells. LL-K12-18 can be used in cancer research .
    LL-K12-18
  • HY-P10257
    KR-12 (human)

    		Bacterial Infection
    KR-12 human is an active segment of LL-37, which exhibits antimicrobial activity against gram-negative bacteria. KR-12 human inhibits E. coli K-12 with MIC of 66 μM .
    KR-12 (human)
  • HY-116788
    Lipofermata
    3 Publications Verification

    		 Bacterial Infection
    Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM .
    Lipofermata
  • HY-E70248
    S-(3-Hydroxydodecanoate)-CoA

    		Endogenous Metabolite Others
    S-(3-Hydroxydodecanoate)-CoACoenzyme A, a Coenzyme A, is a metabolite that can be found or produced in E. coli (strain K12, MG1655) .
    S-(3-Hydroxydodecanoate)-CoA
  • HY-N12320
    Majoranaquinone

    		Antibiotic Infection
    Majoranaquinone exhibits a high antibacterial effect against 4 Staphylococcus, 1 Moraxella, and 1 Enterococcus strains. Majoranaquinone shows substantial efflux pump inhibitory activity in Escherichia coliATCC 25922 strain. Majoranaquinone is found to be an effective biofilm formation inhibitor on E.coli, ATCC 25922 and E. coli K-12 AG100 bacteria .
    Majoranaquinone
  • HY-151357
    MraY-IN-3

    		Bacterial Infection
    MraY-IN-3 (12a) is a potent bacterial translocase MraY inhibitor with an IC50 value of 140 µM. MraY-IN-3 acts on E. coli K12, B. subtilis W23 and P. fluorescens Pf-5 with the MIC50 values of 7 µg/mL, 12 µg/mL, and 46 µg/mL, respectively .
    MraY-IN-3
  • HY-135599
    Lysine hydroxamate

    		Bacterial Infection
    Lysine hydroxamate is an amino acid hydroxamate that inhibits the growth of Escherichia coli K-12. Of the other amino acid hydroxamates tested, only L-lysine hydroxamate reduced the growth rate. The inhibition of growth by L-serine hydroxamate could be rapidly reversed by adding L-serine to the bacterial culture or by removing the analog by filtration. This reversal was specific for L-serine. L-alanine, glycine, or adenine had no effect on the inhibited culture. There was no evidence for active transport of the analog.
    Lysine hydroxamate
  • HY-W844796
    2-Amino-5-methyl-5-hexenoic acid

    (S)-2-Amino-5-methylhex-5-enoic acid

    		 Bacterial Amino Acid Derivatives Infection
    2-Amino-5-methyl-5-hexenoic acid ((S)-2-Amino-5-methylhex-5-enoic acid) is a Methionine analog that competes with methionine and resulting in inhibition of cell growth. 2-Amino-5-methyl-5-hexenoic acid inhibits protein synthesis but not DNA or RNA synthesis in S. typhimurium TA1535 and E. coli K-12 . X
    2-Amino-5-methyl-5-hexenoic acid
  • HY-144728
    MraY-IN-3 hydrochloride

    		Bacterial Infection
    MraY-IN-1 (compound 12a) is a potent  MraY inhibitor with an IC50 value of 140 μM. MraY-IN-1 has antimicrobial activity against Escherichia coli K12, Bacillus subtilis W23 and Pseudomonas fluorescens Pf-5 with MIC50s of 7 µg/mL, 12 µg/mL and 46 µg/mL, respectively. MraY-IN-1 can be used for researching anti-bacteria .
    MraY-IN-3 hydrochloride
  • HY-RS08049
    MAP3K12 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MAP3K12 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP3K12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MAP3K12 Human Pre-designed siRNA Set A
    MAP3K12 Human Pre-designed siRNA Set A
  • HY-163383
    L-Ent-oxPt(IV)

    L-EOP

    		 Bacterial Infection
    L-Ent-oxPt IV (L-EOP) is a Oxaliplatin (HY-17371)-based siderophore-platinum conjugate. L-Ent-oxPt IV exhibits selectivity towards Escherichia coli and antibacterial activity through DNA damage .
    L-Ent-oxPt(IV)
  • HY-118391
    Benzoyl-L-phenylalanine

    N-Benzoyl-L-phenylalanine; Bz-L-Phe-OH

    		 Carboxypeptidase Others
    Benzoyl-L-phenylalanine (N-Benzoyl-L-phenylalanine) is a chorisate mutase-prephenate dehydrogenase inhibitor .
    Benzoyl-L-phenylalanine
  • HY-117709
    BRD6688

    		HDAC Neurological Disease
    BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model .
    BRD6688
  • HY-170484
    KAI-11101

    		MAP3K p38 MAPK Neurological Disease
    KAI-11101 is the inhibitor for dual leucine zipper kinase (DLK, MAP3K12) with a Ki of 0.7 nM. KAI-11101 inhibits Paclitaxel (HY-B0015)-induced cJun phosphorylation (IC50=95 nM) and thus inhibits the activation of MAPK pathway. KAI-11101 is blood brain barrier penetrable and can be further investigated for its neuroprotective property .
    KAI-11101
  • HY-114331
    DLK-IN-1

    		MAP3K FLT3 PAK STK33 Trk Receptor Neurological Disease
    DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research .
    DLK-IN-1
  • HY-156096
    HDAC3-IN-2

    		HDAC Histone Methyltransferase Caspase Apoptosis DNA/RNA Synthesis Cancer
    HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC50: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC50 of 0.55 μM against 4T1 and an IC50 of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels .
    HDAC3-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: